

Biological Studies Experience

	Lp.	Terapeutical area	Active substance	Phase	Route of administration
Biological Studies	1	Peptide hormone	Insulin	Phase III	Subcutaneous
	2	Immunoglobulin	IgPro10	Phase III	Intravenous
	3	Inhibitor of kinase (PI3K)	TGR-1202	Phase III	Oral / Tablets
	4	Inhibitor of kinase (PI3K)	Rigosertib	Phase III	Intravenous
	5	Interleukin inhibitors	Ustekinumab	Phase III	Subcutaneous
	6	Interleukin inhibitors	Guselkumab	Phase III	Subcutaneous
	7	Interleukin inhibitors	Guselkumab	Phase III	Subcutaneous
	8	Proteasome inhibitor	Ixazomib	Phase II	Oral / Tablets
	9	TNF- α inhibitors	Adalimumab	Phase III	Subcutaneous
	10	TNF- α inhibitors	Infliximab	Phase III	Intravenous
	11	TNF- α inhibitors	Adalimumab	Phase III	Subcutaneous
	12	TNF- α inhibitors	Etanercept	Phase III	Subcutaneous
	13	TNF- α inhibitors	Golimumab	Phase III	Intravenous
	14	TNF- α inhibitors	Etanercept	Phase III	Intramuscular
	15	Monoclonal antibodies	Blinatumomab	Phase III	Oral / Tablets
	16	Monoclonal antibodies	Rituximab	Bioequivalence	Intravenous
	17	Monoclonal antibodies	Brentuximab vedotin	Phase III	Intravenous
	18	Monoclonal antibodies	Lenalidomide Dexamethasone Elotuzumab	Phase III	Oral / Tablets
	19	Monoclonal antibodies	Lenalidomide Dexamethasone Elotuzumab	Phase III	Oral / Tablets
	20	Monoclonal antibodies	Rituximab	Phase I	Intravenous
	21	Monoclonal antibodies	REGN846	Phase I	Intravenous
	22	Monoclonal antibodies	Dupilumab	Phase II	Subcutaneous
	23	Monoclonal antibodies	Rituximab	Phase III	Intravenous
	24	Monoclonal antibodies	Daratumumab	Phase III	Intravenous
	25	Monoclonal antibodies	MEDI4736	Phase III	Intravenous
	26	Monoclonal antibodies	Rituximab	Phase III	Intravenous
	27	Monoclonal antibodies	MOR208	Phase II	Intravenous
	28	Monoclonal antibodies	Adalimumab	Phase III	Subcutaneous
	29	Monoclonal antibodies	Tanezumab	Phase III	Intravenous
	30	Monoclonal antibodies	Tanezumab	Phase III	Intravenous
	31	Monoclonal antibodies	Dupilumab	Phase III	Subcutaneous
	32	Monoclonal antibodies	Adalimumab	Phase III	Subcutaneous

Date issue: June 2018

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



21230869/3/Q

Biological Studies Experience

Lp.	Terapeutical area	Active substance	Phase	Route of administration
33	Monoclonal antibodies	Avelumab	Phase III	Intravenous
34	Monoclonal antibodies	Obinutuzumab Atezolizumab Polatuzumab vedotin	Phase I/II	Intravenous
35	Monoclonal antibodies	MEDI4736	Phase I	Intravenous
36	Monoclonal antibodies	AFM11	Phase I	Intravenous
37	Monoclonal antibodies	Adalimumab	Phase I	Subcutaneous
38	Monoclonal antibodies	ALXN1210	Phase III	Intravenous
39	Monoclonal antibodies	Bevacizumab	Phase III	Intravenous
40	Monoclonal antibodies	Pembrolizumab	Phase III	Intravenous
41	Monoclonal antibodies	Adalimumab	Phase III	Subcutaneous

Date issue: June 2018

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



21230869/3/Q